PAD

PAD is a patented LifeNet Health technology that precisely manages the demineralization process to achieve the ideal residual calcium necessary for optimal osteoinductivity.

Over-demineralization can destroy Bone Morphogenic Proteins (BMPs) because the molecules become denatured and rendered ineffective. Under-demineralization compromises osteoinductive performance by preventing the timely release of BMPs.

Strict control of the residual calcium is achieved by enhancing the way the demineralizing acid is applied to the bone. In a series of computer-controlled steps, the vessel containing the bone is rapidly filled (pulsed) with the acid and then drained and neutralized with buffer. This continues until the specific desired residual calcium level is achieved.

A product can be designated as demineralized if the residual calcium level is < 8%. However, studies show that restricted calcium in the range of 1 to 4% provides the most osteoinductive product. This is the range that PAD Technology targets consistently.

LifeNet Health’s PAD demineralization technology is uniquely positioned to improve the inductive properties of allograft bio-implants and support better clinical outcomes, a benefit that serves everyone.

Traditional demineralization processes are competent but not optimal. Without strict control, the ideal residual calcium level cannot be achieved consistently. Patented PAD Technology ensures a predictable quality product that supports osteoinductivity and better clinical outcomes.